BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Fundamental Analysis & Valuation

FRA:BIO3 • DE0005227235

Current stock price

30 EUR
0 (0%)
Last:

This BIO3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BIO3.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BIO3 has reported negative net income.
  • In the past year BIO3 had a positive cash flow from operations.
  • In multiple years BIO3 reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BIO3 reported negative operating cash flow in multiple years.
BIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -1.73%, BIO3 is in the better half of the industry, outperforming 68.49% of the companies in the same industry.
  • BIO3 has a Return On Equity of -4.81%. This is in the better half of the industry: BIO3 outperforms 69.86% of its industry peers.
  • BIO3's Return On Invested Capital of 0.54% is fine compared to the rest of the industry. BIO3 outperforms 76.71% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO3.DE Yearly ROA, ROE, ROICBIO3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

  • The Operating Margin of BIO3 (1.87%) is better than 76.71% of its industry peers.
  • BIO3's Operating Margin has improved in the last couple of years.
  • BIO3 has a Gross Margin (23.19%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of BIO3 has remained more or less at the same level.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO3.DE Yearly Profit, Operating, Gross MarginsBIO3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BIO3.DE Health Analysis

2.1 Basic Checks

  • BIO3 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for BIO3 remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for BIO3 remains at a similar level compared to 5 years ago.
  • BIO3 has a better debt/assets ratio than last year.
BIO3.DE Yearly Shares OutstandingBIO3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO3.DE Yearly Total Debt VS Total AssetsBIO3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 2.04 indicates that BIO3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.04, BIO3 is doing good in the industry, outperforming 65.75% of the companies in the same industry.
  • BIO3 has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO3 would need 46.44 years to pay back of all of its debts.
  • BIO3 has a better Debt to FCF ratio (46.44) than 78.08% of its industry peers.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO3 has dependencies on debt financing.
  • BIO3 has a Debt to Equity ratio of 1.26. This is in the lower half of the industry: BIO3 underperforms 60.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.04
ROIC/WACC0.09
WACC5.93%
BIO3.DE Yearly LT Debt VS Equity VS FCFBIO3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.93 indicates that BIO3 has no problem at all paying its short term obligations.
  • BIO3 has a Current ratio of 4.93. This is in the better half of the industry: BIO3 outperforms 79.45% of its industry peers.
  • BIO3 has a Quick Ratio of 1.66. This is a normal value and indicates that BIO3 is financially healthy and should not expect problems in meeting its short term obligations.
  • BIO3 has a Quick ratio (1.66) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO3.DE Yearly Current Assets VS Current LiabilitesBIO3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BIO3.DE Growth Analysis

3.1 Past

  • The earnings per share for BIO3 have decreased strongly by -117.24% in the last year.
  • The Revenue for BIO3 has decreased by -15.85% in the past year. This is quite bad
  • The Revenue has been growing by 11.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO3.DE Yearly Revenue VS EstimatesBIO3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO3.DE Yearly EPS VS EstimatesBIO3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BIO3 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 19.80, BIO3 is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, BIO3 is valued cheaply inside the industry as 86.30% of the companies are valued more expensively.
  • BIO3's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.54.
Industry RankSector Rank
PE N/A
Fwd PE 19.8
BIO3.DE Price Earnings VS Forward Price EarningsBIO3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BIO3 is valued a bit cheaper than 75.34% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIO3 is valued a bit cheaper than the industry average as 79.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 82.44
EV/EBITDA 33.87
BIO3.DE Per share dataBIO3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BIO3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. BIO3.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.09%, BIO3 is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.63, BIO3 pays a better dividend. On top of this BIO3 pays more dividend than 90.41% of the companies listed in the same industry.
  • With a Dividend Yield of 0.09, BIO3 pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

  • The dividend of BIO3 is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • The dividend of BIO3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO3.DE Yearly Income VS Free CF VS DividendBIO3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO3.DE Fundamentals: All Metrics, Ratios and Statistics

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (5/23/2025, 1:53:46 PM)

30

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19B
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.8
P/S 1.87
P/FCF 82.44
P/OCF 82.44
P/B 2.33
P/tB 2.41
EV/EBITDA 33.87
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY5.05%
FCF(TTM)0.36
FCFY1.21%
OCF(TTM)0.36
OCFY1.21%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.04
F-Score3
WACC5.93%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A

BIOTEST AG-VORZUGSAKTIEN / BIO3.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE.


Can you provide the valuation status for BIOTEST AG-VORZUGSAKTIEN?

ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG-VORZUGSAKTIEN (BIO3.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for BIOTEST AG-VORZUGSAKTIEN?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a profitability rating of 4 / 10.